Interim report January - June 2010

 <li> The Group's sales for the period amounted to SEK 265 (333) million.

<li> EBITDA amounted to SEK 27 (54) million.

<li> Operating profit totalled SEK -9* (43) million.

<li> The net profit after tax for the period amounted to SEK -34* (15) million

<li> Earnings per share after tax for the period were SEK -0.11 (0.04 ) before
and after dilution



Significant events during the period

<li> I mpairment of SEK 24 million on intangible assets and SEK 7 million on
inventories.

<li> Niklas Prager elected as the new Chairman of the Board of BioPhausia.

<li> BioPhausia becomes the main supplier of parallel-imported pharmaceuticals
to Apoteksgruppen.



Significant events after the period

<li> Maris Hartmanis has taken up the position of new BioPhausia CEO on 9
August.

<li> The Board has decided to streamline operations and focus on the Nordic
region.



Period April - June

<li> The Group's sales for the period amounted to SEK 134 (153) million.

<li> EBITDA amounted to SEK 9 (26) million.

<li> Operating profit totalled SEK -20* (20) million.

<li> The net profit after tax for the period amounted to SEK -35* (6) million

<li> Earnings per share after tax for the period were SEK -0.10 (0.02 ) before
and after dilution



*Includes one-off costs: impairment of intangible assets, SEK 24 million,
impairment of inventories, SEK 7 million, and costs associated with the change
of CEO, SEK 4 million (SEK 1 million in Q2).



[HUG#1441276]